5 amino 1mq side effects high dose 5-AMINO-1MQ 5-Amino-1MQ Results: Week-by-Week Timeline (2026)

It changes which shelf it belongs on

The advantages of GLP-1 agonists include substantial clinical trial data supporting their efficacy and safety, FDA approval for weight management in certain populations, proven results with many users losing 15-20% or more of body weight, and effects on appetite that make caloric restriction feel natural

At the molecular level, 5-amino-1MQ functions as a competitive inhibitor of NNMT, demonstrating remarkable potency with an IC of 1.2 0.1 M under standard assay conditions (50 M SAM, 100 M nicotinic acid). This represents a dramatic 10-fold improvement over the parent compound 1-methylquinolinium, achieved through strategic amino group substitution that enhances binding affinity to the NNMT active site. The compound's mechanism centers on preventing the methylation of nicotinamide to 1-methylnicotinamide (1-MNA), thereby preserving nicotinamide for recycling back to NAD+ through the salvage pathway. This intervention effectively blocks what researchers have termed the "NNMT metabolic drain" a process that simultaneously depletes NAD+ precursors and consumes cellular methylation capacity

Understanding how 5-amino-1mq fits this landscape helps researchers develop coherent protocols that address their specific goals

It burns through nicotinamide, which your cells would otherwise recycle into NAD+, and it spends SAM, the body's main methyl currency